Global mRNA Vaccine Core Enzyme Market Growth 2025-2031

Publication ID:

LPI04253483

Publication Date:

April 22, 2025

Pages:

119

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global mRNA Vaccine Core Enzyme market size is predicted to grow from US$ 1920 million in 2025 to US$ 1641 million in 2031; it is expected to grow at a CAGR of -2.6% from 2025 to 2031.
mRNA-vaccines can efficiently activate both components of the immune system, i.e., T-cell and humoral responses. The essential advantage of mRNA vaccines includes fast, inexpensive, scalable and uniform production providing a large output of desirable products in vitro. Synthesis and purification processes significantly simplify the process technology of mRNA drugs with injectable purity. Thus, mRNA production via in vitro transcription is more advantageous as compared with DNA-vaccines since it is a chemical process without the use of cells. mRNA techniques make it possible to pass all the phases of vaccine development much faster in comparison with the production of vaccines based on inactivated viruses or recombinant proteins. This property is critically important when designing vaccines against viral pathogens as the main problem of disease control includes a time gap between an epidemic and vaccine development. mRNA vaccine core enzyme is the key raw material in the production of mRNA vaccine and drugs.
The core manufacturers of mRNA Vaccine Core Enzyme mainly include Thermo Fisher, NEB, TriLink Bio Technologies, Merck, etc. The top four companies in the industry account for about 49% of the market. North America is the largest market, accounting for about 38% of the global market share. In terms of product type, Capping Enzyme have the largest market share of about 25%. From an application perspective, Biopharmaceutical Companies account for the largest share at around 84%.
The 鈥渕RNA Vaccine Core Enzyme Industry Forecast鈥� looks at past sales and reviews total world mRNA Vaccine Core Enzyme sales in 2024, providing a comprehensive analysis by region and market sector of projected mRNA Vaccine Core Enzyme sales for 2025 through 2031. With mRNA Vaccine Core Enzyme sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world mRNA Vaccine Core Enzyme industry.
This Insight Report provides a comprehensive analysis of the global mRNA Vaccine Core Enzyme landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on mRNA Vaccine Core Enzyme portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global mRNA Vaccine Core Enzyme market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for mRNA Vaccine Core Enzyme and breaks down the forecast by Enzyme Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global mRNA Vaccine Core Enzyme.
This report presents a comprehensive overview, market shares, and growth opportunities of mRNA Vaccine Core Enzyme market by product type, application, key manufacturers and key regions and countries.
Segmentation by Enzyme Type:
Capping Enzyme
2'-O-Methyltransferase
Inorganic Pyrophosphatase
Poly (A) Polymerase
Rnase Inhibitor
RNA Polymerase
Restriction Enzyme
Dnase I
Others
Segmentation by Application:
Biopharmaceutical Companies
Academic and Research Institutions
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Thermo Fisher
NEB
TriLink Bio Technologies
Merck
Aldevron
Qiagen N.V.
Promega
Roche CustomBiotech
Takara Bio Inc.
Novoprotein
Vazyme
Hongene Biotech Corporatio
Yeasen Biotechnology
Key Questions Addressed in this Report
What is the 10-year outlook for the global mRNA Vaccine Core Enzyme market?
What factors are driving mRNA Vaccine Core Enzyme market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do mRNA Vaccine Core Enzyme market opportunities vary by end market size?
How does mRNA Vaccine Core Enzyme break out by Enzyme Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global mRNA Vaccine Core Enzyme Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for mRNA Vaccine Core Enzyme by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for mRNA Vaccine Core Enzyme by Country/Region, 2020, 2024 & 2031
2.2 mRNA Vaccine Core Enzyme Segment by Enzyme Type
2.2.1 Capping Enzyme
2.2.2 2'-O-Methyltransferase
2.2.3 Inorganic Pyrophosphatase
2.2.4 Poly (A) Polymerase
2.2.5 Rnase Inhibitor
2.2.6 RNA Polymerase
2.2.7 Restriction Enzyme
2.2.8 Dnase I
2.2.9 Others
2.3 mRNA Vaccine Core Enzyme Sales by Enzyme Type
2.3.1 Global mRNA Vaccine Core Enzyme Sales Market Share by Enzyme Type (2020-2025)
2.3.2 Global mRNA Vaccine Core Enzyme Revenue and Market Share by Enzyme Type (2020-2025)
2.3.3 Global mRNA Vaccine Core Enzyme Sale Price by Enzyme Type (2020-2025)
2.4 mRNA Vaccine Core Enzyme Segment by Application
2.4.1 Biopharmaceutical Companies
2.4.2 Academic and Research Institutions
2.5 mRNA Vaccine Core Enzyme Sales by Application
2.5.1 Global mRNA Vaccine Core Enzyme Sale Market Share by Application (2020-2025)
2.5.2 Global mRNA Vaccine Core Enzyme Revenue and Market Share by Application (2020-2025)
2.5.3 Global mRNA Vaccine Core Enzyme Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global mRNA Vaccine Core Enzyme Breakdown Data by Company
3.1.1 Global mRNA Vaccine Core Enzyme Annual Sales by Company (2020-2025)
3.1.2 Global mRNA Vaccine Core Enzyme Sales Market Share by Company (2020-2025)
3.2 Global mRNA Vaccine Core Enzyme Annual Revenue by Company (2020-2025)
3.2.1 Global mRNA Vaccine Core Enzyme Revenue by Company (2020-2025)
3.2.2 Global mRNA Vaccine Core Enzyme Revenue Market Share by Company (2020-2025)
3.3 Global mRNA Vaccine Core Enzyme Sale Price by Company
3.4 Key Manufacturers mRNA Vaccine Core Enzyme Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers mRNA Vaccine Core Enzyme Product Location Distribution
3.4.2 Players mRNA Vaccine Core Enzyme Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for mRNA Vaccine Core Enzyme by Geographic Region
4.1 World Historic mRNA Vaccine Core Enzyme Market Size by Geographic Region (2020-2025)
4.1.1 Global mRNA Vaccine Core Enzyme Annual Sales by Geographic Region (2020-2025)
4.1.2 Global mRNA Vaccine Core Enzyme Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic mRNA Vaccine Core Enzyme Market Size by Country/Region (2020-2025)
4.2.1 Global mRNA Vaccine Core Enzyme Annual Sales by Country/Region (2020-2025)
4.2.2 Global mRNA Vaccine Core Enzyme Annual Revenue by Country/Region (2020-2025)
4.3 Americas mRNA Vaccine Core Enzyme Sales Growth
4.4 APAC mRNA Vaccine Core Enzyme Sales Growth
4.5 Europe mRNA Vaccine Core Enzyme Sales Growth
4.6 Middle East & Africa mRNA Vaccine Core Enzyme Sales Growth
5 Americas
5.1 Americas mRNA Vaccine Core Enzyme Sales by Country
5.1.1 Americas mRNA Vaccine Core Enzyme Sales by Country (2020-2025)
5.1.2 Americas mRNA Vaccine Core Enzyme Revenue by Country (2020-2025)
5.2 Americas mRNA Vaccine Core Enzyme Sales by Enzyme Type (2020-2025)
5.3 Americas mRNA Vaccine Core Enzyme Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC mRNA Vaccine Core Enzyme Sales by Region
6.1.1 APAC mRNA Vaccine Core Enzyme Sales by Region (2020-2025)
6.1.2 APAC mRNA Vaccine Core Enzyme Revenue by Region (2020-2025)
6.2 APAC mRNA Vaccine Core Enzyme Sales by Enzyme Type (2020-2025)
6.3 APAC mRNA Vaccine Core Enzyme Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe mRNA Vaccine Core Enzyme by Country
7.1.1 Europe mRNA Vaccine Core Enzyme Sales by Country (2020-2025)
7.1.2 Europe mRNA Vaccine Core Enzyme Revenue by Country (2020-2025)
7.2 Europe mRNA Vaccine Core Enzyme Sales by Enzyme Type (2020-2025)
7.3 Europe mRNA Vaccine Core Enzyme Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa mRNA Vaccine Core Enzyme by Country
8.1.1 Middle East & Africa mRNA Vaccine Core Enzyme Sales by Country (2020-2025)
8.1.2 Middle East & Africa mRNA Vaccine Core Enzyme Revenue by Country (2020-2025)
8.2 Middle East & Africa mRNA Vaccine Core Enzyme Sales by Enzyme Type (2020-2025)
8.3 Middle East & Africa mRNA Vaccine Core Enzyme Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of mRNA Vaccine Core Enzyme
10.3 Manufacturing Process Analysis of mRNA Vaccine Core Enzyme
10.4 Industry Chain Structure of mRNA Vaccine Core Enzyme
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 mRNA Vaccine Core Enzyme Distributors
11.3 mRNA Vaccine Core Enzyme Customer
12 World Forecast Review for mRNA Vaccine Core Enzyme by Geographic Region
12.1 Global mRNA Vaccine Core Enzyme Market Size Forecast by Region
12.1.1 Global mRNA Vaccine Core Enzyme Forecast by Region (2026-2031)
12.1.2 Global mRNA Vaccine Core Enzyme Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global mRNA Vaccine Core Enzyme Forecast by Enzyme Type (2026-2031)
12.7 Global mRNA Vaccine Core Enzyme Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Thermo Fisher
13.1.1 Thermo Fisher Company Information
13.1.2 Thermo Fisher mRNA Vaccine Core Enzyme Product Portfolios and Specifications
13.1.3 Thermo Fisher mRNA Vaccine Core Enzyme Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Thermo Fisher Main Business Overview
13.1.5 Thermo Fisher Latest Developments
13.2 NEB
13.2.1 NEB Company Information
13.2.2 NEB mRNA Vaccine Core Enzyme Product Portfolios and Specifications
13.2.3 NEB mRNA Vaccine Core Enzyme Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 NEB Main Business Overview
13.2.5 NEB Latest Developments
13.3 TriLink Bio Technologies
13.3.1 TriLink Bio Technologies Company Information
13.3.2 TriLink Bio Technologies mRNA Vaccine Core Enzyme Product Portfolios and Specifications
13.3.3 TriLink Bio Technologies mRNA Vaccine Core Enzyme Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 TriLink Bio Technologies Main Business Overview
13.3.5 TriLink Bio Technologies Latest Developments
13.4 Merck
13.4.1 Merck Company Information
13.4.2 Merck mRNA Vaccine Core Enzyme Product Portfolios and Specifications
13.4.3 Merck mRNA Vaccine Core Enzyme Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Merck Main Business Overview
13.4.5 Merck Latest Developments
13.5 Aldevron
13.5.1 Aldevron Company Information
13.5.2 Aldevron mRNA Vaccine Core Enzyme Product Portfolios and Specifications
13.5.3 Aldevron mRNA Vaccine Core Enzyme Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Aldevron Main Business Overview
13.5.5 Aldevron Latest Developments
13.6 Qiagen N.V.
13.6.1 Qiagen N.V. Company Information
13.6.2 Qiagen N.V. mRNA Vaccine Core Enzyme Product Portfolios and Specifications
13.6.3 Qiagen N.V. mRNA Vaccine Core Enzyme Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Qiagen N.V. Main Business Overview
13.6.5 Qiagen N.V. Latest Developments
13.7 Promega
13.7.1 Promega Company Information
13.7.2 Promega mRNA Vaccine Core Enzyme Product Portfolios and Specifications
13.7.3 Promega mRNA Vaccine Core Enzyme Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Promega Main Business Overview
13.7.5 Promega Latest Developments
13.8 Roche CustomBiotech
13.8.1 Roche CustomBiotech Company Information
13.8.2 Roche CustomBiotech mRNA Vaccine Core Enzyme Product Portfolios and Specifications
13.8.3 Roche CustomBiotech mRNA Vaccine Core Enzyme Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Roche CustomBiotech Main Business Overview
13.8.5 Roche CustomBiotech Latest Developments
13.9 Takara Bio Inc.
13.9.1 Takara Bio Inc. Company Information
13.9.2 Takara Bio Inc. mRNA Vaccine Core Enzyme Product Portfolios and Specifications
13.9.3 Takara Bio Inc. mRNA Vaccine Core Enzyme Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Takara Bio Inc. Main Business Overview
13.9.5 Takara Bio Inc. Latest Developments
13.10 Novoprotein
13.10.1 Novoprotein Company Information
13.10.2 Novoprotein mRNA Vaccine Core Enzyme Product Portfolios and Specifications
13.10.3 Novoprotein mRNA Vaccine Core Enzyme Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Novoprotein Main Business Overview
13.10.5 Novoprotein Latest Developments
13.11 Vazyme
13.11.1 Vazyme Company Information
13.11.2 Vazyme mRNA Vaccine Core Enzyme Product Portfolios and Specifications
13.11.3 Vazyme mRNA Vaccine Core Enzyme Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Vazyme Main Business Overview
13.11.5 Vazyme Latest Developments
13.12 Hongene Biotech Corporatio
13.12.1 Hongene Biotech Corporatio Company Information
13.12.2 Hongene Biotech Corporatio mRNA Vaccine Core Enzyme Product Portfolios and Specifications
13.12.3 Hongene Biotech Corporatio mRNA Vaccine Core Enzyme Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Hongene Biotech Corporatio Main Business Overview
13.12.5 Hongene Biotech Corporatio Latest Developments
13.13 Yeasen Biotechnology
13.13.1 Yeasen Biotechnology Company Information
13.13.2 Yeasen Biotechnology mRNA Vaccine Core Enzyme Product Portfolios and Specifications
13.13.3 Yeasen Biotechnology mRNA Vaccine Core Enzyme Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Yeasen Biotechnology Main Business Overview
13.13.5 Yeasen Biotechnology Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂